Format
Sort by

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 157

1.

Systematic review: comparative effectiveness of medications to reduce risk for primary breast cancer.

Nelson HD, Fu R, Griffin JC, Nygren P, Smith ME, Humphrey L.

Ann Intern Med. 2009 Nov 17;151(10):703-15, W-226-35. doi: 10.7326/0003-4819-151-10-200911170-00147. Review.

PMID:
19920271
2.

Use of medications to reduce risk for primary breast cancer: a systematic review for the U.S. Preventive Services Task Force.

Nelson HD, Smith ME, Griffin JC, Fu R.

Ann Intern Med. 2013 Apr 16;158(8):604-14. doi: 10.7326/0003-4819-158-8-201304160-00005. Review.

PMID:
23588749
3.

Chemoprevention of breast cancer: a summary of the evidence for the U.S. Preventive Services Task Force.

Kinsinger LS, Harris R, Woolf SH, Sox HC, Lohr KN.

Ann Intern Med. 2002 Jul 2;137(1):59-69. Review.

PMID:
12093250
4.

Tamoxifen for the prevention of breast cancer: current status of the National Surgical Adjuvant Breast and Bowel Project P-1 study.

Fisher B, Costantino JP, Wickerham DL, Cecchini RS, Cronin WM, Robidoux A, Bevers TB, Kavanah MT, Atkins JN, Margolese RG, Runowicz CD, James JM, Ford LG, Wolmark N.

J Natl Cancer Inst. 2005 Nov 16;97(22):1652-62.

5.

Short and long term effects of tibolone in postmenopausal women.

Formoso G, Perrone E, Maltoni S, Balduzzi S, D'Amico R, Bassi C, Basevi V, Marata AM, Magrini N, Maestri E.

Cochrane Database Syst Rev. 2012 Feb 15;(2):CD008536. doi: 10.1002/14651858.CD008536.pub2. Review.

PMID:
22336846
6.

Effects of tamoxifen vs raloxifene on the risk of developing invasive breast cancer and other disease outcomes: the NSABP Study of Tamoxifen and Raloxifene (STAR) P-2 trial.

Vogel VG, Costantino JP, Wickerham DL, Cronin WM, Cecchini RS, Atkins JN, Bevers TB, Fehrenbacher L, Pajon ER Jr, Wade JL 3rd, Robidoux A, Margolese RG, James J, Lippman SM, Runowicz CD, Ganz PA, Reis SE, McCaskill-Stevens W, Ford LG, Jordan VC, Wolmark N; National Surgical Adjuvant Breast and Bowel Project (NSABP).

JAMA. 2006 Jun 21;295(23):2727-41. Epub 2006 Jun 5. Erratum in: JAMA. 2006 Dec 27;296(24):2926. JAMA. 2007 Sep 5;298(9):973.

PMID:
16754727
7.

Update of the National Surgical Adjuvant Breast and Bowel Project Study of Tamoxifen and Raloxifene (STAR) P-2 Trial: Preventing breast cancer.

Vogel VG, Costantino JP, Wickerham DL, Cronin WM, Cecchini RS, Atkins JN, Bevers TB, Fehrenbacher L, Pajon ER, Wade JL 3rd, Robidoux A, Margolese RG, James J, Runowicz CD, Ganz PA, Reis SE, McCaskill-Stevens W, Ford LG, Jordan VC, Wolmark N; National Surgical Adjuvant Breast and Bowel Project.

Cancer Prev Res (Phila). 2010 Jun;3(6):696-706. doi: 10.1158/1940-6207.CAPR-10-0076. Epub 2010 Apr 19.

8.

Chemoprevention of breast cancer.

Thomsen A, Kolesar JM.

Am J Health Syst Pharm. 2008 Dec 1;65(23):2221-8. doi: 10.2146/ajhp070663. Review.

PMID:
19020189
9.

Future possibilities in the prevention of breast cancer: breast cancer prevention trials.

Cuzick J.

Breast Cancer Res. 2000;2(4):258-63. Epub 2000 May 19. Review.

10.

Chemoprevention of breast cancer. A joint guideline from the Canadian Task Force on Preventive Health Care and the Canadian Breast Cancer Initiative's Steering Committee on Clinical Practice Guidelines for the Care and Treatment of Breast Cancer.

Levine M, Moutquin JM, Walton R, Feightner J; Canadian Task Force on Preventive Health Care and the Canadian Breast Cancer Initiative's Steering Committee on Clinical Practice Guidelines for the Care and Treatment of Breast Cancer.

CMAJ. 2001 Jun 12;164(12):1681-90. Review.

11.

From adjuvant therapy to breast cancer prevention: BCPT and STAR.

Dunn BK, Ford LG.

Breast J. 2001 May-Jun;7(3):144-57. Review.

PMID:
11469927
12.

Risks, benefits, and effects on quality of life of selective estrogen-receptor modulator therapy in postmenopausal women at increased risk of breast cancer.

Ganz PA, Land SR.

Menopause. 2008 Jul-Aug;15(4 Suppl):797-803. doi: 10.1097/gme.0b013e31817be9af. Review.

PMID:
18596601
13.

American Society of Clinical Oncology technology assessment on breast cancer risk reduction strategies: tamoxifen and raloxifene.

Chlebowski RT, Collyar DE, Somerfield MR, Pfister DG.

J Clin Oncol. 1999 Jun;17(6):1939-55. Review.

PMID:
10561236
14.

The effects of tibolone in older postmenopausal women.

Cummings SR, Ettinger B, Delmas PD, Kenemans P, Stathopoulos V, Verweij P, Mol-Arts M, Kloosterboer L, Mosca L, Christiansen C, Bilezikian J, Kerzberg EM, Johnson S, Zanchetta J, Grobbee DE, Seifert W, Eastell R; LIFT Trial Investigators.

N Engl J Med. 2008 Aug 14;359(7):697-708. doi: 10.1056/NEJMoa0800743.

15.

Overview of the main outcomes in breast-cancer prevention trials.

Cuzick J, Powles T, Veronesi U, Forbes J, Edwards R, Ashley S, Boyle P.

Lancet. 2003 Jan 25;361(9354):296-300. Review.

PMID:
12559863
16.
17.

Weighing the risks and benefits of tamoxifen treatment for preventing breast cancer.

Gail MH, Costantino JP, Bryant J, Croyle R, Freedman L, Helzlsouer K, Vogel V.

J Natl Cancer Inst. 1999 Nov 3;91(21):1829-46. Review. Erratum in: J Natl Cancer Inst 2000 Feb 2;92(3):275.

18.

Exemestane for primary prevention of breast cancer in postmenopausal women.

Zhang Y, Simondsen K, Kolesar JM.

Am J Health Syst Pharm. 2012 Aug 15;69(16):1384-8. doi: 10.2146/ajhp110585.

PMID:
22855103
19.
20.

American society of clinical oncology clinical practice guideline update on the use of pharmacologic interventions including tamoxifen, raloxifene, and aromatase inhibition for breast cancer risk reduction.

Visvanathan K, Chlebowski RT, Hurley P, Col NF, Ropka M, Collyar D, Morrow M, Runowicz C, Pritchard KI, Hagerty K, Arun B, Garber J, Vogel VG, Wade JL, Brown P, Cuzick J, Kramer BS, Lippman SM; American Society of Clinical Oncology.

J Clin Oncol. 2009 Jul 1;27(19):3235-58. doi: 10.1200/JCO.2008.20.5179. Epub 2009 May 26.

Items per page

Supplemental Content

Write to the Help Desk